HSV-2 vaccine (HSV529) / Sanofi, Merck (MSD) - LARVOL DELTA

Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. (PubMed, Viruses) - "Notably, several vaccines-SL-V20, HF10, VC2, and mRNA-1608-have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections."

Journal • Review • Herpes Simplex • Infectious Disease

Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine. (PubMed, JCI Insight) - "The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2-specific TRB repertoire requires tissue-based evaluation."

IO biomarker • Journal • CD4 • NR4A1

Nonclinical safety evaluation of two vaccine candidates for Herpes Simplex Virus type 2 to support combined administration in humans. (PubMed, J Appl Toxicol) - "Three repeated-dose toxicity studies, one in guinea pigs and two in rabbits, were conducted to assess systemic toxicity and local tolerance of HSV529, alone or adjuvanted with GLA-SE, or G103 containing GLA-SE. Data from these studies show that both vaccines are safe and well tolerated and support the ongoing HSV-2 clinical trial in which the two vaccine candidates will be given either sequentially or concomitantly to explore their potential synergistic and incremental effects."

Journal • CNS Disorders • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease

Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus (HSV) Seronegative Recipients of the HSV529 Vaccine. (PubMed, J Infect Dis) - "HSV2 gD antibody was detected in cervicovaginal fluid at about one-third the level of that in serum. A vaccine that induces potent serum antibodies transported to the genital tract might reduce HSV genital infection."

Journal • Herpes Simplex

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus 2 Vaccine, HSV529, in Adults With or Without HSV Infection. (PubMed, J Infect Dis) - P1 | "HSV529 vaccine was safe and elicited neutralizing antibody and modest CD4+ T-cell responses in HSV seronegative vaccinees.Clinical Trials Registration. NCT01915212."

Clinical • Journal • P1 data • Herpes Simplex • Immunology

Detection of residual proteins UL5 and UL29 using a targeted proteomics approach in HSV529, a replication deficient HSV-2 vaccine candidate. (PubMed, J Pharm Sci) - "Results show that residual UL5 and UL29 proteins can be detected in the HSV529 candidate and that MRM analysis provides the appropriate sensitivity and specificity required for quantitation. The transition from nano-flow to ultra-performance driven chromatography was found to improve method robustness without compromising the sensitivity of the assay."

Journal